Randomization
Phase 3Small molecule
Randomization is one of 37 small molecule programs targeting Effectiveness. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Effectiveness
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPhase 3
Mounjaro
Eli LillyPhase 3
Actos
TakedaPhase 3
Nicotine Free Cigarettes
PfizerPhase 3
Botulinum Toxin a
GSKPhase 3
Gemzar
Johnson & JohnsonPhase 2
Droxia
TTheravia
Phase 2
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Pneumococcal Conjugate Vaccine
NovartisPhase 3
Silver Diamine Fluoride
TThe University of Hong Kong
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Effectiveness1 trial
Microcirculation1 trial
PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor
Unknown status·FFundacion Investigacion Interhospitalaria Cardiovascular·Phase 4·NCT02698618·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Randomization. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IInsud Pharma